News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Concerns with Merck & Co., Inc. (JOBS) Cholesterol Study
July 10, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Merck & Co Inc shares fell 3.8 percent on Thursday amid speculation its Zetia cholesterol medicine fared poorly in a clinical trial comparing it with Abbott Laboratories' Niaspan in preventing plaque build-up in arteries.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
MORE ON THIS TOPIC
Women’s Health
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain
July 2, 2025
·
1 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH IQVIA
Understanding the FDA’s AI Guidance in Pharmacovigilance
July 1, 2025
·
1 min read
·
Lori Ellis
Psychedelics
Beckley’s Psychedelic Nasal Spray Clears Phase II Depression Study
July 1, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
FDA Signs Off on Neurogene’s ‘Best-Case Scenario’ Pivotal Study Design for Rett Syndrome
July 1, 2025
·
2 min read
·
Tristan Manalac